• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lantern Pharma Inc. - Common Stock (NQ:LTRN)

    3.260 -0.100 (-2.98%)
    Streaming Delayed Price Updated: 3:59 PM EST, Jan 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 30,080
    Open 3.400
    Bid (Size) 3.030 (200)
    Ask (Size) 3.500 (3,000)
    Prev. Close 3.360
    Today's Range 3.223 - 3.405
    52wk Range 2.550 - 6.118
    Shares Outstanding 11,184,423
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Establishes AI Center of Excellence and Advanced Agentic Labs in India
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
    From Lantern Pharma Inc.
    Via Business Wire

    Performance

    YTD
    +4.8%
    +4.8%
    1 Month
    -3.3%
    -3.3%
    3 Month
    -26.1%
    -26.1%
    6 Month
    -18.3%
    -18.3%
    1 Year
    -12.8%
    -12.8%

    More News

    Read More
    News headline image
    New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television
    Via ACCESS Newswire
    BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
    From Lantern Pharma Inc.
    Via Business Wire
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Lantern Pharma Earnings Preview ↗
    Via Benzinga
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST
    Via ACCESS Newswire
    News headline image
    Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows
    Via ACCESS Newswire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
    From Lantern Pharma Inc.
    Via Business Wire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
    From Lantern Pharma Inc.
    Via Business Wire
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 30
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
    From Lantern Pharma Inc.
    Via Business Wire
    BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Advancing Drug Discovery with PredictBBB.ai(TM) Partnership
    Via Investor Brand Network
    Topics Artificial Intelligence
    MissionIRNewsBreaks – RADR(R) Platform Powers Lantern Pharma Inc.’s (NASDAQ: LTRN) Push Into Rare Pediatric Brain Cancer Treatment
    Via Investor Brand Network
    Topics Artificial Intelligence
    Lantern Pharma Inc. (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESS Newswire
    Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill

    Frequently Asked Questions

    Is Lantern Pharma Inc. - Common Stock publicly traded?
    Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
    What exchange does Lantern Pharma Inc. - Common Stock trade on?
    Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
    The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
    What is the current price of Lantern Pharma Inc. - Common Stock?
    The current price of Lantern Pharma Inc. - Common Stock is 3.260
    When was Lantern Pharma Inc. - Common Stock last traded?
    The last trade of Lantern Pharma Inc. - Common Stock was at 01/13/26 03:59 PM ET
    What is the market capitalization of Lantern Pharma Inc. - Common Stock?
    The market capitalization of Lantern Pharma Inc. - Common Stock is 36.46M
    How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
    Lantern Pharma Inc. - Common Stock has 36M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.